J0695
J0695 – Injection, ceftolozane 50 mg and tazobactam 25 mg · NDC Crosswalk & Billing Units
HCPCS Level II J-code · Medicare Part B drug billing
J-code
● 1 NDC crosswalked per 75mg (50mg cft/25mg taz) $10.038/unit ASP+6%
📋 J0695 summary
J0695 is a HCPCS Level II J-code used to bill ceftolozane 50 mg and tazobactam 25 mg, billed per 75mg (50mg cft/25mg taz). The number of billing units to report depends on the dose administered and the NDC/package billed — use the calculator below.
Brand names associated with J0695: Zerbaxa
Code J0695
Billing unit 75mg (50mg cft/25mg taz) Payment limit $10.038/unit NDC-Crosswalk 1
Quarter Q3 2026
RxCUI Atlas Trace the drug concept →
⚠ An NDC↔HCPCS crosswalk and a published payment limit do not guarantee payer coverage or payment. Always verify the current payer policy and claim format before billing.
🗂️ Key billing facts
HCPCS codeJ0695
DescriptorInjection, ceftolozane 50 mg and tazobactam 25 mg
Billing unit75mg (50mg cft/25mg taz)
Payment limit / unit$10.038
Est. ASP / unit$9.470 est.
Mapped NDCs1
Data periodQ3 2026
Last updated2026-08-20
💊 About Ceftolozane and Tazobactam Injection DRUG GUIDE
Zerbaxa (ceftolozane and tazobactam) is used to treat three types of serious bacterial infections in adults and children born at least 32 weeks gestational age.
For complicated intra-abdominal infections (serious infections inside the belly), Zerbaxa is always given alongside another antibiotic called metronidazole.
It also treats complicated urinary tract infections, including kidney infections (pyelonephritis).Zerbaxa is also approved to treat hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia — lung infections that develop in the hospital or while a patient is on a breathing machine.
It works only against specific bacteria confirmed or strongly suspected to be causing the infection.
Clinical overview from our editorial drug guide for Ceftolozane and Tazobactam Injection. For billing reference, see the sections above.
🧾 Billing & reimbursement HCPCS · CMS · EFF. Q3 2026
📅 Payment limits effective Q3 2026 — from the CMS Medicare Part B Payment Limit File (revised quarterly).
Medicare payment limit / unit
$10.038
Est. ASP / unit
$9.470 est.
Est. after 2% sequester
$9.837
HCPCS dosage
75mg (50mg cft/25mg taz)
The CMS payment limit is the Medicare Part B drug allowance (ASP + 6%, statutory). After the 2% federal sequester the effective payment is ≈ ASP + 4.3%; estimated ASP = payment limit ÷ 1.06. Source: CMS Medicare Part B Payment Limit File (quarterly), Q3 2026.
Full HCPCS code details (official CMS record)
Long descriptionInjection, ceftolozane 50 mg and tazobactam 25 mg
CoverageC — Carrier/MAC judgment
Pricing indicator51 — Drug — priced under the ASP methodology
Type of service1 — Medical care
BETOS-2O1E
ASC payment groupYY
Action codeN — No maintenance this year
Effective date2016-01-01
Date added2016-01-01
Source: CMS HCPCS Level II code file (imported via admin).
🧮 Dosing & billing-units calculator HCPCS UNITS
One billing unit of J0695 = 75 mg. Enter a regimen to convert dose → billing units and project a full course.
Billing units = dose ÷ HCPCS unit size. Most payers require whole units — round per the payer's policy. “Est. Medicare pay” uses the current payment limit. For single-dose vials, drug discarded after administration may be separately billable with modifier JW (JZ when none is discarded) where allowed. Always verify payer-specific rounding before billing.
🔁 NDCs that bill under J0695 WITH EST. MEDICARE PAY
1 NDC map to J0695. Bill units = how many HCPCS units one package represents. Est. pay / pkg = payment limit ($10.038/unit) × that package's bill units.
| NDC (11-digit) | Drug | Labeler | Package | Strength | Bill units | Est. pay / pkg | NADAC / unit | Status | Source |
|---|---|---|---|---|---|---|---|---|---|
| 67919-0030-01 | ZERBAXA ceftolozane and tazobactam 1 g/10mL; .5 g/10mL INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION | Merck | 10 VIAL, SINGLE-DOSE in 1 CARTON (67919-03... | 1 g/10mL; .5 g/10mL | 200 | $2,007.60 | — | ● Active | CMS + PDAC |
NDC→HCPCS mappings come from the CMS ASP NDC-HCPCS crosswalk; additional DME MAC / DMEPOS mappings come from PDAC and are labeled separately. NADAC from CMS (weekly). “Status” reflects the product's marketing / obsolete flag in the NDC directory. Presence or absence here does not determine Medicare coverage. Linked NDCs open the full product page.
📊 Medicare utilization & spend CMS · PART B · 2026 (Q1)
Period
Total Part B spend
$112.1K
Claims
136
Beneficiaries
50
Spend / beneficiary
$2,241.98
Spend / claim
$824.26
Trend by period
Where J0695 ranks among Part B drugs · 2026 (Q1) · neighbors ±5
Total spending — #558 of 824
#553
MULTIHANCE A9577
$123.5K
#554
ENGERIX-B ADULT(9074... 90740
$122.1K
#555
AVYCAZ J0714
$119.7K
#556
EMTRICITABINE-TENOFO... J0750
$118.9K
#557
EVOMELA J9246
$116.9K
#558
ZERBAXA J0695
$112.1K
#559
ETOPOPHOS* J9181
$111.1K
#560
TEMODAR J9328
$109.5K
#561
VIBATIV J3095
$109.2K
#562
ACTIVATE MATRIX, PER... Q4301
$109.2K
#563
EDARAVONE* J1301
$108.3K
Total claims — #597 of 824
#592
MESNA* J9209
142
#593
AMNIOBAND, GUARDIAN... Q4151
142
#594
CIPROFLOXACIN-D5W J0744
140
#595
TEMSIROLIMUS* J9330
137
#596
XERAVA J0122
136
#597
ZERBAXA J0695
136
#598
KIMYRSA J2406
133
#599
ACETAMINOPHEN(J0136) J0136
132
#600
METRO IV* J1836
132
#601
VIBATIV J3095
131
#602
ARTACENT WOUND, PER... Q4169
131
Top Medicare Part B drugs by the selected metric. Click any drug to open its J-code page. Source: CMS Medicare Quarterly Part B Spending by Drug.
Full breakdown by period (2)
| Period | Total spend | Beneficiaries | Claims | $/beneficiary | $/claim |
|---|---|---|---|---|---|
| 2026 (Q1) | $112.1K | 50 | 136 | $2,241.98 | $824.26 |
| 2025 (Q1-Q4) | $481.5K | 135 | 586 | $3,566.45 | $821.62 |
Provider-administered (Part B) spend, calculated for the whole HCPCS code (CMS does not publish Medicare spend per individual NDC). Self-administered use is covered under Part D instead. A blank patient count means fewer than 11 people — CMS hides counts that small to protect privacy. Source: CMS Medicare Quarterly Part B Spending by Drug (data.cms.gov), updated quarterly.
📈 Medicare Part B claims detail CMS PSPS · 2024
Calendar-year 2024 Medicare Part B fee-for-service activity for this HCPCS code, summed across all carriers, localities and specialties (CMS Physician/Supplier Procedure Summary). A “service” is one billed line/unit — not one claim — so counts run higher than claim counts.
Allowed charges
$247.6K
Medicare paid
$193.3K
Submitted services
220,675
Denial rate
86.8%
Allowed / service
$8.50
Submitted charges
$5.21M
Source: CMS Physician/Supplier Procedure Summary (PSPS), CY2024 — Medicare Part B carrier + DME fee-for-service claims (excludes Medicare Advantage). Figures are for the whole HCPCS code, which may cover uses beyond this drug. ⚠ CMS hides any figure covering fewer than 11 patients (a privacy rule), so totals — especially denials and low-volume codes — run a little low.
🗺️ Where J0695 is utilized CMS · BY PROVIDER · 2024
Medicare Part B services for this code by the rendering provider's state — 24 services across 1 states & territories in 2024 (CMS reports include DC and U.S. territories). Switch to per 100k to compare states fairly regardless of population. Hover or tap a state for its top ZIP codes.
Hover or tap a state to see its numbers + top ZIP codes.
Per-capita = services ÷ 2023 state population × 100,000 (so high-population states aren't automatically "hotter"). Counts reflect the provider's location, not the patient's. Providers with fewer than 11 patients are hidden by CMS for privacy, so totals run low and per-100k can be noisy in small states — read this as relative geography, not exact counts. Source: CMS Medicare Physician & Other Practitioners — by Provider and Service, 2024.
📊 What bills under J0695
J-codes are billing codes often used for drugs billed under the medical benefit. This connects the billing code to the NDC package records it covers, by ingredient and labeler.
NDC products by ingredient
NDC products by labeler
🗃️ Data sources & freshness
Every figure on this page is computed from public datasets. Here's what each section draws on and how current it is.
HCPCS code & descriptor
CMS HCPCS Level II code file
Loaded
Payment limit & billing unit
CMS Medicare Part B ASP Pricing File (quarterly)
Q3 2026 · as of 2026-08-20
NDC ↔ HCPCS crosswalk
CMS ASP NDC-HCPCS crosswalk + DMEPDAC (PDAC)
1 NDC mapped
NADAC acquisition cost
CMS National Average Drug Acquisition Cost (weekly)
Not available for mapped NDCs
Utilization & spend
CMS Part B Spending by Drug · PSPS · Physician & Other Practitioners
Latest data year 2026
Figures are estimates for reference and may lag the source files. Always verify against the current CMS files and your payer's policy before submitting claims.
⚠️ Practical billing caveats
- A crosswalk is not coverage. An NDC mapping or a published payment limit does not guarantee a payer will cover or pay this code. Check the specific plan's policy.
- Units ≠ milligrams. Bill the number of HCPCS units (dose ÷ the code's unit size), not the milligram dose. Use the calculator above.
- Discarded drug. For single-dose vials, drug discarded after administration may be separately billable with modifier JW (and JZ when nothing is discarded) where the payer allows.
- Rounding & partial units. Many payers require whole units; round per the payer's policy, not automatically up.
- The code can cover more than this drug. Some HCPCS codes span multiple products or strengths — confirm the exact code for the product administered.
- Figures lag. ASP limits change quarterly and utilization data are released with a delay. Verify against the current CMS files before billing.
❓ J0695 billing FAQ
What is HCPCS code J0695?
J0695 is a HCPCS Level II J-code used to bill Injection, ceftolozane 50 mg and tazobactam 25 mg under Medicare Part B and most medical (not pharmacy) benefits.
What is the billing unit for J0695?
One unit of J0695 represents 75mg (50mg cft/25mg taz). Report the number of units equal to the dose administered divided by 75mg (50mg cft/25mg taz).
How many units of J0695 should I bill?
Divide the dose administered by the code's unit size (75mg (50mg cft/25mg taz)) to get the number of billing units, then round per your payer's policy. The calculator on this page converts a dose into billing units and projects a full course.
How much does Medicare pay for J0695?
The Medicare Part B payment limit is $10.038 per unit (Q3 2026), based on ASP + 6%. After the 2% sequester the effective payment is about $9.837 per unit. Payment limits are revised quarterly.
Which NDCs bill under J0695?
1 NDC currently map to J0695 in the CMS ASP NDC-HCPCS crosswalk. See the NDC crosswalk table above for each product, package, billing units and estimated reimbursement.
Does a crosswalk mean J0695 is covered?
No. An NDC-to-HCPCS crosswalk and a published payment limit do not guarantee coverage or payment. Coverage depends on the payer, the diagnosis and the site of care — always verify the current policy before billing.
For professional billing reference only — verify against the current CMS files before submitting claims.